Howard S. Hochster, MD
Can the novel agent arfolitixorin supplant leucovorin calcium, a widely used component of combination regimens for patients with metastatic colorectal cancer (mCRC)? Investigators are seeking to answer that question in a phase III trial now underway.
Investigators are seeking to recruit at least 440 participants at sites in the United States, Canada, Western Europe, and Japan. The primary end point of the parallel-group study is objective response rate (ORR). Secondary end points are progression-free survival (PFS) and duration of response.
Figure. ARFOX With Bevacizumab in Advanced CRC
... to read the full story